Cargando…
Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
Introduction Women with a pathogenic BRCA1/2 mutation have a markedly increased lifetime risk of developing breast and/or ovarian cancer. The current preventive treatment alternatives that are offered are an intensified breast cancer screening programme and risk-reducing operations. Before deciding...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216782/ https://www.ncbi.nlm.nih.gov/pubmed/34168381 http://dx.doi.org/10.1055/a-1326-1792 |
_version_ | 1783710487389667328 |
---|---|
author | Krassuski, Lisa Marlene Kautz-Freimuth, Sibylle Vennedey, Vera Rhiem, Kerstin Schmutzler, Rita K. Stock, Stephanie |
author_facet | Krassuski, Lisa Marlene Kautz-Freimuth, Sibylle Vennedey, Vera Rhiem, Kerstin Schmutzler, Rita K. Stock, Stephanie |
author_sort | Krassuski, Lisa Marlene |
collection | PubMed |
description | Introduction Women with a pathogenic BRCA1/2 mutation have a markedly increased lifetime risk of developing breast and/or ovarian cancer. The current preventive treatment alternatives that are offered are an intensified breast cancer screening programme and risk-reducing operations. Before deciding on one option, medical and personal factors such as life situation and individual preferences must be weighed carefully. Decision aids are used internationally to support BRCA1/2 mutation carriers during their decision-making process. In this study these are analysed structurally for the first time and their applicability to the German context is examined. Material and Methods A systematic literature search in five electronic databases and a manual search were performed. The identified decision aids were evaluated with regard to formal criteria, medical content and quality. The qualitative assessment used the criteria of the International Patient Decision Aid Standards Collaboration (IPDASi v4.0), which examined various dimensions (e.g., information, probabilities, values). Results Twenty decision aids, which were published between 2003 and 2019 in Australia (n = 4), the United Kingdom (n = 3), Canada (n = 2), the Netherlands (n = 2) and the USA (n = 9), were included. Nine focus on BRCA1/2 mutation carriers and eleven include other risk groups. Eighteen include risk-reducing operations as decision options, 14 list screening methods for breast and/or ovarian cancer, and 13 describe the possibility of pharmacological prevention by means of selective oestrogen receptor modulators or aromatase inhibitors. Nine of the 20 decision aids meet fundamental quality criteria (IPDASi v4.0 qualification criteria). Conclusion International decision aids can serve formally as a basis for a German decision aid for BRCA1/2 mutation carriers. Some of them differ markedly in content from the recommendations of German guidelines. Only a few achieve a high quality. |
format | Online Article Text |
id | pubmed-8216782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-82167822021-06-23 Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review Krassuski, Lisa Marlene Kautz-Freimuth, Sibylle Vennedey, Vera Rhiem, Kerstin Schmutzler, Rita K. Stock, Stephanie Geburtshilfe Frauenheilkd Introduction Women with a pathogenic BRCA1/2 mutation have a markedly increased lifetime risk of developing breast and/or ovarian cancer. The current preventive treatment alternatives that are offered are an intensified breast cancer screening programme and risk-reducing operations. Before deciding on one option, medical and personal factors such as life situation and individual preferences must be weighed carefully. Decision aids are used internationally to support BRCA1/2 mutation carriers during their decision-making process. In this study these are analysed structurally for the first time and their applicability to the German context is examined. Material and Methods A systematic literature search in five electronic databases and a manual search were performed. The identified decision aids were evaluated with regard to formal criteria, medical content and quality. The qualitative assessment used the criteria of the International Patient Decision Aid Standards Collaboration (IPDASi v4.0), which examined various dimensions (e.g., information, probabilities, values). Results Twenty decision aids, which were published between 2003 and 2019 in Australia (n = 4), the United Kingdom (n = 3), Canada (n = 2), the Netherlands (n = 2) and the USA (n = 9), were included. Nine focus on BRCA1/2 mutation carriers and eleven include other risk groups. Eighteen include risk-reducing operations as decision options, 14 list screening methods for breast and/or ovarian cancer, and 13 describe the possibility of pharmacological prevention by means of selective oestrogen receptor modulators or aromatase inhibitors. Nine of the 20 decision aids meet fundamental quality criteria (IPDASi v4.0 qualification criteria). Conclusion International decision aids can serve formally as a basis for a German decision aid for BRCA1/2 mutation carriers. Some of them differ markedly in content from the recommendations of German guidelines. Only a few achieve a high quality. Georg Thieme Verlag KG 2021-06 2021-06-21 /pmc/articles/PMC8216782/ /pubmed/34168381 http://dx.doi.org/10.1055/a-1326-1792 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Krassuski, Lisa Marlene Kautz-Freimuth, Sibylle Vennedey, Vera Rhiem, Kerstin Schmutzler, Rita K. Stock, Stephanie Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review |
title |
Decision Aids for Preventive Treatment Alternatives for
BRCA1/2
Mutation Carriers: a Systematic Review
|
title_full |
Decision Aids for Preventive Treatment Alternatives for
BRCA1/2
Mutation Carriers: a Systematic Review
|
title_fullStr |
Decision Aids for Preventive Treatment Alternatives for
BRCA1/2
Mutation Carriers: a Systematic Review
|
title_full_unstemmed |
Decision Aids for Preventive Treatment Alternatives for
BRCA1/2
Mutation Carriers: a Systematic Review
|
title_short |
Decision Aids for Preventive Treatment Alternatives for
BRCA1/2
Mutation Carriers: a Systematic Review
|
title_sort | decision aids for preventive treatment alternatives for
brca1/2
mutation carriers: a systematic review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216782/ https://www.ncbi.nlm.nih.gov/pubmed/34168381 http://dx.doi.org/10.1055/a-1326-1792 |
work_keys_str_mv | AT krassuskilisamarlene decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview AT kautzfreimuthsibylle decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview AT vennedeyvera decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview AT rhiemkerstin decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview AT schmutzlerritak decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview AT stockstephanie decisionaidsforpreventivetreatmentalternativesforbrca12mutationcarriersasystematicreview |